Mark H. Ebell

Mark H. Ebell

Auto-generated profile, based on publicly available information

Mark H. Ebell

Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2004 in The Journal of the American Board of Family Medicine
Verified
Journal Article
Closed access
PDF file
MEMark H. Ebell
Mark H. Ebell
JSJay Siwek
Jay Siwek
BWBarry D. Weiss
Barry D. Weiss
SWSteven H. Woolf
Steven H. Woolf
JSJeffrey Susman
Jeffrey Susman
MBMarjorie Bowman
Marjorie Bowman
A large number of taxonomies are used to rate the quality of an individual study and the strength of a recommendation based on a body of evidence. We have developed a new grading scale that will be used by several family medicine and primary care journals (required or optional), with the goal of allowing readers to learn one taxonomy that will apply to many sources of evidence. Our scale is called the Strength of Recommendation Taxonomy. It addresses the quality, quantity, and consistency of evidence and allows authors to rate individual studies or bodies of evidence. The taxonomy is built around the information mastery framework, which emphasizes the use of patient-oriented outcomes that measure changes in morbidity or mortality. An A-level recommendation is based on consistent and good quality patient-oriented evidence; a B-level recommendation is based on inconsistent or limited quality patient-oriented evidence; and a C-level recommendation is based on consensus, usual practice, opinion, disease-oriented evidence, or case series for studies of diagnosis, treatment, prevention, or screening. Levels of evidence from 1 to 3 for individual studies also are defined. We hope that consistent use of this taxonomy will improve the ability of authors and readers to communicate about the translation of research into practice.

2 March 2018 in Public Health Reviews
Verified
Journal Article
Open access
PDF file
MEMark H. Ebell
Mark H. Ebell
TTThuy Nhu Thai
Thuy Nhu Thai
KRKyle J. Royalty
Kyle J. Royalty
Recommendations regarding cancer screening vary from country to country, and may also vary within countries depending on the organization making the recommendations. The goal of this study was to summarize the cancer screening recommendations from the 21 countries with the highest per capita spending on healthcare. Cancer screening guidelines were identified for each country based on a review of the medical literature, internet searches, and contact with key informants in most countries. The highest level recommendation was identified for each country, in the order of national recommendation, cancer society recommendation, or medical specialty society recommendation. Breast cancer screening recommendations were generally consistent across countries, most commonly recommending mammography biennially from ages 50 to 69 or 70 years. In the USA, specialty societies generally offered more intensive screening recommendations. All countries also recommend cervical cancer screening, although there is some heterogeneity regarding the test (cytology or HPV or both) and the age of initiation and screening interval. Most countries recommend colorectal cancer screening using fecal immunochemical (FIT) testing, while only seven countries recommend general or selective screening for prostate cancer, and a similar number explicitly recommend against screening for prostate cancer. Screening for lung and skin cancer is only recommended by a few countries. Greater per capita healthcare expenditures are not associated with greater screening intensity, with the possible exception of prostate cancer. Guidelines for cancer screening differ between countries, with areas of commonality but also clear differences. Recommendations have important commonalities for well-established cancer screening programs such as breast and cervical cancer, with greater variation between countries regarding prostate, colorectal, lung, and skin cancer screening. Ideally, recommendations should be made by a professionally diverse, independent panel of experts that make evidence-based recommendations regarding screening based on the benefits, harms, and available resources in that country’s context.

11 November 2013 in JAMA Internal Medicine
Verified
Journal Article
Open access
PDF file
MEMark H. Ebell
Mark H. Ebell
WJWoncheol Jang
Woncheol Jang
YSYe Shen
Ye Shen
RGRomergryko G. Geocadin
Romergryko G. Geocadin
In-hospital cardiac arrest (IHCA) is common in the inpatient setting. In 1 study of 13 400 patients admitted over 2 years at a teaching hospital, approximately 2.5% experienced an episode of IHCA.1 Data from more than 400 hospitals participating in Get With the Guidelines Registry–Resuscitation (GWTG-R) found that there are an estimated 192 000 treated episodes of IHCA annually in US hospitals, an event rate of 0.92 per 1000 patient days.2 Quiz Ref ID Overall survival to discharge after treated IHCA is approximately 18%, with about half of those patients neurologically intact or with only mild neurologic deficits at discharge.3,4 Because IHCA is common and has potentially devastating outcomes, discussion of patient wishes regarding resuscitation or “code status” is important. Do-not-attempt-resuscitation (DNAR) orders are written when cardiopulmonary resuscitation (CPR) is unlikely to meet the patient’s treatment goals of long-term, neurologically intact survival.5 Presumably, information about prognosis would be helpful as part of a shared decision regarding DNAR orders.

1 March 2016 in American Journal of Preventive Medicine
Verified
Journal Article
Closed access
MEMark H. Ebell
Mark H. Ebell
MCMaryBeth B. Culp
MaryBeth B. Culp
TRTaylor J. Radke
Taylor J. Radke

1 February 2004
Verified
Journal Article
Closed access
MEMark H Ebell
Mark H Ebell
JSJay Siwek
Jay Siwek
BWBarry D Weiss
Barry D Weiss
SWSteven H Woolf
Steven H Woolf
JSJeffrey Susman
Jeffrey Susman
MBMarjorie Bowman
Marjorie Bowman

22 January 2024 in The Annals of Family Medicine
Verified
Journal Article
Open access
PDF file
MEMark H. Ebell
Mark H. Ebell
HBHenry C. Barry
Henry C. Barry
KBKanishka Baduni
Kanishka Baduni
GGGabrielle Grasso
Gabrielle Grasso
PURPOSE We conducted a meta-analysis to evaluate clinically meaningful benefits and harms of monoclonal antibodies targeting amyloid in patients with Alzheimer dementia. METHODS We searched PubMed, Cochrane CENTRAL, and 5 trial registries, as well as the reference lists of identified studies. We included randomized controlled trials comparing a monoclonal antibody with placebo at a dose consistent with that used in phase 3 trials or for Food and Drug Administration approval. Studies had to report at least 1 clinically relevant benefit or harm. Data were extracted independently by at least 2 researchers for random effects meta-analysis. Changes in cognitive and functional scales were compared between groups, and each difference was assessed to determine if it met the minimal clinically important difference (MCID). RESULTS We identified 19 publications with 23,202 total participants that evaluated 8 anti-amyloid antibodies. There were small improvements over placebo in the Alzheimer’s Disease Assessment Scale (ADAS)-Cog-11 to -14 score (standardized mean difference = −0.07; 95% CI, −0.10 to −0.04), Mini Mental State Examination score (0.32 points; 95% CI, 0.13 to 0.50), and Clinical Dementia Rating-Sum of Boxes scale score (mean difference =−0.18 points; 95% CI, −0.34 to −0.03), and the combined functional scores (standardized mean difference = 0.09; 95% CI, 0.05 to 0.13). None of the changes, including those for lecanemab, aducanumab, and donanemab, exceeded the MCID. Harms included significantly increased risks of amyloid-related imaging abnormalities (ARIA)-edema (relative risk [RR] = 10.29; number needed to harm [NNH] = 9), ARIA-hemorrhage (RR = 1.74; NNH = 13), and symptomatic ARIA-edema (RR = 24.3; NNH = 86). CONCLUSIONS Although monoclonal antibodies targeting amyloid provide small benefits on cognitive and functional scales in patients with Alzheimer dementia, these improvements are far below the MCID for each outcome and are accompanied by clinically meaningful harms.